Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.
Our findings explores the emerging evidence that inhaled corticosteroids (ICS) may be less effective in current smokers compared with nonsmokers with chronic obstructive pulmonary disorder (COPD), says Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester.
The findings were presented at the 2024 European Respiratory Society International Congress.
Transcript
What specific advantages does long-acting β-agonist plus long-acting muscarinic agonist (LABA+LAMA) therapy offer over LABA plus ICS in managing COPD symptoms in current smokers?
There have been studies suggesting that the inhaled corticosteroids are not as effective in current smokers compared to ex-smokers. In our analysis of the FLAME trial, we tried to see whether that's true, and our study seems to support this opinion. So, among ex-smokers, we found the anticipated association between eosinophils and treatment response. In people with low blood eosinophils, we found out that a combination of a long-acting β-agonist with a long-acting muscarinic [agonist] was superior to LABA+ICS. And then in higher blood eosinophils, we found a trend over better response to LABA+ICS compared to LABA+LAMA.
Then when we looked at groups of patients that we know from our analysis are respondents—people who have a significant suppression of their blood eosinophils on inhaled steroids—in this group of patients, in ex-smokers, LABA+ICS was superior to LABA+LAMA; that's as we would have expected. Now, when we looked at the subgroup of current smokers, LABA+LAMA was consistently superior to LABA+ICS, and that tell us that probably current smokers don't get the same benefit from inhaled corticosteroids.
How might the findings from the FLAME trial post hoc analysis influence treatment guidelines for patients with COPD who are current smokers, particularly those with varying eosinophil counts?
Our post hoc analysis of the FLAME trial is an exploratory study, so we still need to validate our findings. We have a good message, but we need to further validate the results before having strong enough evidence to inform guidelines. So, what we have been doing is that we have started an individual participant data meta-analysis called the ICS-RECODE study, and we have applied and gained access to data from 20 mega trials looking at the effectiveness of inhaled corticosteroids for COPD. And we are reanalyzing these trials and trying to look at predictors of treatment response. One of the predictors that we are looking at is the smoking state, to show if this meta-analysis confirms the findings that smokers appear resistant to inhaled corticosteroids, then I believe, that will be the time to inform the guidelines.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More